• Login
    Browsing 2 Conference Abstracts by Title 
    •   Home
    • 2 Conference Abstracts
    • Browsing 2 Conference Abstracts by Title
    •   Home
    • 2 Conference Abstracts
    • Browsing 2 Conference Abstracts by Title
    Mar 06, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CommunityTitleAuthorsSubjectsPublisherJournal

    Browsing 2 Conference Abstracts by Title

    • 0-9
    • A
    • B
    • C
    • D
    • E
    • F
    • G
    • H
    • I
    • J
    • K
    • L
    • M
    • N
    • O
    • P
    • Q
    • R
    • S
    • T
    • U
    • V
    • W
    • X
    • Y
    • Z

    xmlui.ArtifactBrowser.ConfigurableBrowse.view

    Sort by:

    Order:

    Results:

    Now showing items 1-20 of 127

    • List view
    • Grid view
    • title
    • issue date
    • submit date
    • ascending
    • descending
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
      • Thumbnail

        2007 Epicentre Scientific Day Abstracts

        2007
      • Thumbnail

        2008 Epicentre Scientific Day Abstracts

        2008
      • Thumbnail

        28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials

        Simon, J; Kennedy, S; Mahon, B; Dubey, S; Grant-Klein, R; Liu, K; Hartzel, J; Coller, B; Welebob, C; Hanson, M; et al. (Oxford University Press, 2020-09-20)
        Background The recent Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo highlights the sustained threat of EVD morbidity and mortality where healthcare and vaccine delivery are challenging. ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was developed by Merck & Co., Inc., Kenilworth, NJ, USA in collaboration with multiple partners to prevent EVD and has been approved for human use in several countries. Methods We pooled data from three Phase 2/3 clinical trials conducted in Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL) during the 2013–2016 West African outbreak to assess immune responses using a validated assay in each of the three studies and performed a post hoc analysis by sex, age (18–50 yrs & >50 yrs) and baseline (BL) GP-enzyme-linked immunosorbent assay (ELISA) titer (< 200 & ≥200 EU/ml). The full analysis set (FAS) population included the primary immunogenicity populations (all vaccinated participants with serology data collected within an acceptable day range) from all three trials. The endpoints were total IgG antibody response (EU/mL) measured by the GP-ELISA and neutralizing antibody response measured by the plaque reduction neutralization test (PRNT) to rVSVΔG-ZEBOV-GP at Days 14, 28, 180, and 365 postvaccination. Results In the overall population and in all subgroups, GP-ELISA and PRNT geometric mean titers increased from BL, with most peaking at Day 28 and persisting through Day 365. There were differences between males and females and between participants with BL GP-ELISA < 200 & ≥200 EU/ml. There did not appear to be a difference between age groups. Conclusion These data demonstrate that rVSVΔG-ZEBOV-GP elicits a robust and durable immune response up to 12 months in participants regardless of age, sex, or BL GP-ELISA titer. The higher immune responses observed in females and participants with preexisting immunity are consistent with those described in published literature for other vaccines.
      • Thumbnail

        Accelerated HIV testing for PMTCT in maternity and labour wards is vital to capture mothers at a critical point in the programme at district level

        Beltman, JJ; Fitzgerald, M; Buhendwa, L; Moens, M; Zachariah, R; Kazima, J; Allde, N (2006)
      • Thumbnail

        Achieving universal access to antiretroviral therapy in a rural district in Malawi: how was it done?

        Massaquoi, M; Nalingunkwi, R; Von Pilar, U; Mwagomba, B; Bemelmans, M; Zachariah, R; Harries, A D (2008-08)
      • Thumbnail

        Added value of bleach sedimentation microscopy for diagnosis of pulmonary tuberculosis: cost-effectiveness study

        Bonnet, Maryline; Tajahmady, A; Guithuy, W; Ramsay, A; Gagnidze, L; Varaine, F (2008-10)
      • Thumbnail

        Analysis of clinical and immunological outcomes of an HIV positive paediaric cohort treated at Mpilo Hospital in Bulawayo, Zimbabwe

        Nyathi, M N; Ndebele, W; Alons, E; Palma, Pedro Pablo; Roddy, Paul (2008-08)
      • Thumbnail

        Anti-retroviral therapy (ART) outcomes in children <13 years of age in resource-limeted countries (RLCs): a Médecins Sans Frontières (MSF) cohort

        Olson, David; MSF HIV/AIDS Working Group (2006)
      • Thumbnail

        Anti-tuberculosis drug resistance survey in West Nile, Uganda

        Ahoua, Laurence; Sauvageot, D; Edemaga, D; Martin, A; Umutoni, C; Odama, A; Omale, W; Olson, D; Bonte, L; Adatu-Engwau, M; et al. (2008-10)
      • Thumbnail

        Antiretroviral Therapy in Intravenous Drug Users: Results from a Comprehensive Routine HIV Care Project in Nanning, Southern China Guangxi Zhuang Autonomous Region

        Durier, N; Loke, C; Yang, Y; Tang, Z; Balkan, Suna; Lu, Z; Sauvageot, D (2006)
      • Thumbnail

        Antiretroviral treatment can be successfull within a prison setting: The experience from Bangkwang Central Prison, Thailand.

        Srisuphanthavorn, M; Chayatub, B; Chua, Arlene; Ngammee, V; Cavallier, Philippe; Zachariah, R; Wilson, David (2006)
      • Thumbnail

        Antiretroviral treatment outcomes in patients who received rifampicin together with nevirapine or efavirenz.

        Van Cutsem G; Hilderbrand K; Boulle, A; Cohen, Karen; Goemaere, Eric; MSF Brussels (2008-03-19)
      • Thumbnail

        Appropriate counseling approach to disclose HIV status to HIV-infected children: Chiradzulu, Malawi

        Bouithy, N; Chimbudzi, F; Makata, T; Le Paih, M; Jeannin, A; Szumilin, Elisabeth; Munger, A; Blasco, P; PcGuire (2008-08)
      • Thumbnail

        Brief Summary of MSF Medical Publications 2010

        Brinkman, Matthew; Yun, Oliver; MSF USA (2010)
      • Thumbnail

        Burden of cervical abnormalities and cancer in a cohort of HIV-infected women in Mumbai, India

        Isaakidis P; Pimple S; Varghese B; Da Silva E; Mansoor H; Ladomirska J; Sharma N; Caluwaerts S; Reid T; MSF OCB (2011-09)
      • Thumbnail

        Cervial cancer screening among HIV-positive women in rural Cambodia: a pilot programme

        Raguenaud, Marie-Eve; Isaakidis, P; Khim, S A; Ping, C; Kim, C; Martello, L; Reid, Tony (2008-08)
      • Thumbnail

        The challenge of HIV/AIDS communication in the Islamic community in Thailand

        Lawan, Sarovat; Anchan, Singchai (2006)
      • Thumbnail

        The Challenges of Integrating HIV Prevention and Care into Existing Health Services in Resource-Limited Settings

        Cirera, A; Mitjavilla, F; Villa, L; Mansilla, C; Morote, S; Ibanez, F (2006)
      • Thumbnail

        Cholera epidemic control

        Zachariah, R (Malawi Medical Association, 2001)
      • Thumbnail

        Chronic Hepatitis B treatment outcomes in HIV co-infected patients in Mumbai, India

        Isaakidis P; Mansoor H; Varghese B; Da Silva E; Deshpande A; Dal Molin T; Arnould L; Zachariah R; Reid T; MSF OCB (2011-09)
        DSpace software (copyright © 2002 - 2021)  DuraSpace
        Quick Guide | Contact Us
        Open Repository is a service operated by 
        Atmire NV
         

        Export search results

        The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

        By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

        To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

        After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.